ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with ...
Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency AskBio Inc. (AskBio), a ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity” or 'the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
A new UK-wide research collaboration acclerating development of promising new treatments and precision diagnostics for ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...
A new national research collaboration designed to speed up the development of promising new treatments and precision ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Stockhead on MSN
Lunch Wrap: ASX wobbles as war uncertainty brews; Cochlear clipped in brutal sell-off
Markets are looking wobbly again midweek as the Hormuz blockade lingers despite ceasefire talk. ... Read More The post Lunch ...
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous ...
A novel method for directing mitochondria to specific cells could reshape how scientists approach diseases driven by cellular dysfunction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results